Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
SpringWorks Therapeutics
SpringWorks Therapeutics
(SWTX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ogsiveo
Nirogacestat
2023-11-27
2025-2043
Desmoid tumors
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
MIRDAMETINIB
lung neoplasms
,
neurofibrosarcoma
,
nerve sheath neoplasms
,
liver diseases
,
hepatic insufficiency
,
healthy volunteers/patients
,
neoplasms
,
neurofibromatosis 1
,
neurofibromatoses
,
neurofibroma
,
non-small-cell lung carcinoma
,
colorectal neoplasms
,
plexiform neurofibroma
,
breast neoplasms
,
glioma
,
melanoma
,
colonic neoplasms
,
triple negative breast neoplasms
,
adenocarcinoma
,
adenocarcinoma of lung
,
congenital abnormalities
,
hemangioma
,
vascular malformations
,
arteriovenous malformations
,
lymphangioma
,
lymphatic abnormalities
,
cystic lymphangioma
,
histiocytosis
,
langerhans-cell histiocytosis
,
juvenile xanthogranuloma
,
sinus histiocytosis
,
liposarcoma
,
myxoid liposarcoma
,
multiple myeloma
,
b-cell chronic lymphocytic leukemia
,
autonomic nervous system diseases
,
histiocytic sarcoma
Nirogacestat
healthy volunteers/patients
,
neoplasms
,
ovarian neoplasms
,
granulosa cell tumor
,
desmoid tumors
,
fibroma
,
aggression
Benzimidazole
drug interactions
Terfenadine
allergic rhinitis seasonal
,
rhinitis
,
allergic rhinitis
,
pemphigus
,
allergic rhinitis perennial
Bevifimod
type 1 diabetes mellitus
,
graft rejection
,
alpha 1-antitrypsin deficiency
,
emphysema
,
pulmonary emphysema
,
graft vs host disease
LIFIRAFENIB
neoplasms
Nepidermin
hypercholesterolemia
,
dyslipidemias
Endocrine
hypogonadism
Antineoplaston a10
diarrhea
,
clostridium infections
,
hypertension
,
pulmonary hypertension
Pd0332991
healthy volunteers/patients
,
pancreatic neoplasms
,
precursor b-cell lymphoblastic leukemia-lymphoma
,
castration-resistant prostatic neoplasms
,
endometrioid carcinoma
,
fallopian tube neoplasms
,
peritoneal neoplasms
,
melanoma
,
colorectal neoplasms
,
urinary bladder neoplasms
,
unknown primary neoplasms
,
pancreatic ductal carcinoma
,
liver failure
,
hepatic insufficiency
,
renal insufficiency
,
myelodysplastic syndromes
,
preleukemia
,
acute disease
,
non-small-cell lung carcinoma
,
lung neoplasms
,
carcinoma
,
triple negative breast neoplasms
,
multiple myeloma
,
head and neck neoplasms
,
ovarian neoplasms
,
non-hodgkin lymphoma
,
adenocarcinoma
,
leukemia
,
precursor cell lymphoblastic leukemia-lymphoma
,
lymphoma
,
mantle-cell lymphoma
,
sarcoma
,
renal cell carcinoma
,
squamous cell carcinoma
,
squamous cell neoplasms
,
lymphoid leukemia
,
ovarian epithelial carcinoma
,
kidney neoplasms
,
plasma cell neoplasms
,
colonic neoplasms
,
bone neoplasms
,
neuroblastoma
,
medulloblastoma
,
rhabdoid tumor
,
ewing sarcoma
,
rhabdomyosarcoma
,
diffuse intrinsic pontine glioma
,
small cell lung carcinoma
,
animal mammary neoplasms
,
intraductal carcinoma noninfiltrating
,
b-cell lymphoma
,
prostatic neoplasms
,
brain neoplasms
,
second primary neoplasms
,
glioma
,
oligodendroglioma
,
transitional cell carcinoma
,
myeloid leukemia acute
,
myeloid leukemia
,
hepatocellular carcinoma
,
liver neoplasms
,
glioblastoma
,
gliosarcoma
,
astrocytoma
,
liposarcoma
,
kidney diseases
,
urologic neoplasms
,
urogenital neoplasms
,
urologic diseases
,
neoplasms by site
,
glandular and epithelial neoplasms
,
neoplasms
,
squamous cell carcinoma of head and neck
,
neoplasm metastasis
,
male breast neoplasms
,
recurrence
,
breast neoplasms
,
radiotherapy
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use